T-cells Archives

News and Trends 20 Oct 2022

Tiziana Life Sciences looks to phase 1 trial for intranasal Alzheimer’s drug

Tiziana Life Sciences Ltd. says it plans to submit an investigational new drug (IND) application for a phase 1 trial of intranasal foralumab in Alzheimer’s disease patients. It comes after the company received an affirmative written response from the FDA on a pre-investigational new drug application (PIND). Tiziana plans on filing the IND for Alzheimer’s […]

October 20, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 18 Oct 2022

Emergex develops vaccine for smallpox and monkeypox

Emergex Vaccines Holding Limited has formulated and confirmed the synthesis and assembly of a CD8+ T cell adaptive vaccine for smallpox and monkeypox, made up predominantly of early “eclipse phase” antigens. The monkeypox virus is part of the same family of double-stranded DNA viruses (Poxviridae) as variola virus, the virus that causes smallpox; they share […]

October 18, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 13 Oct 2022

T-cell therapy platform trial begins in adults with blood cancers

SMART102, a human T-lymphoid progenitor cell injection derived from cord blood using Smart Immune’s ProTcell platform, has entered clinical testing. The trial is being sponsored and led by Great Paris University Hospitals (AP-HP). Smart Immune SAS is a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell therapy platform to fully and rapidly re-arm the immune […]

October 13, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 3 Oct 2022

Estrella and TradeUP merge to become publicly traded company

Estrella Biopharma, Inc. and TradeUP Acquisition Corp. have entered into a definitive business combination agreement that will result in Estrella becoming a publicly listed company. Upon closing of the transaction, TradeUP will be renamed Estrella Immunopharma, Inc. Estrella Biopharma is a preclinical-stage biopharmaceutical company developing CD19-targeted ARTEMIS T-cell therapies under certain license agreements with the […]

October 3, 2022 - 3 minutesmins - By Jim Cornall

CAR-T cell therapy, cancer therapy, cell therapy

News and Trends 3 Oct 2022

AmplifyBio acquires PACT Pharma assets

AmplifyBio has acquired select assets from PACT Pharma, Inc., a privately held biopharmaceutical company developing neoantigen-specific T cell receptor cell therapies. The deal will provide AmplifyBio with advanced characterization platforms, bioinformatics capabilities, and 40 drug development experts to enhance its own cell and gene therapy service offerings. AmplifyBio will also acquire the South San Francisco […]

October 3, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 16 Sep 2022

Marengo advancing its lead TCR activator into clinic after FDA clearance

Marengo Therapeutics is advancing its lead TCR activator, STAR0602, into clinic following clearance of its investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA). STAR0602 is a bi-functional fusion antibody that deploys a mechanism of T cell activation that has demonstrated potent single agent activity in PD-1 refractory settings in preclinical […]

September 16, 2022 - 2 minutesmins - By Liza Laws

News and Trends 5 Sep 2022

First patient with peripheral T cell lymphoma dosed with Yingli Pharma’s linperlisib

The first patient has been dosed in a phase 2 trial looking at a drug to treat peripheral T cell lymphomas – a heterogenous group of generally aggressive neoplasms. Yingli Pharma made the announcement on Saturday (September 3) that patients were being dosed with linperlisib – a potent inhibitor of the delta isoform of PI3 […]

September 5, 2022 - 2 minutesmins - By Liza Laws

News and Trends 1 Sep 2022

License agreement signed allowing drug to treat mycosis fungoides to expand in Asia, Australia and the Middle East

A license agreement has been signed between Helsinn Group and Juniper Biologics further widening the scope for distribution of T-cell lymphoma treatment, LEGADA. The license signifies a supply agreement to register, distribute, promote, market and sell the drug in Australia, Asia and the Middle East as a topical treatment of the mycosis fungoides-type cutaneous T-cell […]

September 1, 2022 - 3 minutesmins - By Liza Laws

covid-19 vaccine emergency use authorization

News and Trends 29 Aug 2022

AIVITA Biomedical announces publication of trial results of its COVID-19 vaccine

Safety and efficacy results from phase 1 and 2 clinical trials looking at a Covid-19 vaccine made at point-of-care by third party personnel have been published. AIVITA Biomedical Inc., a biotech specializing in cell applications, made the announcement today (August 29). The results were published in the article in the journal Human Vaccines & Immunotherapeutics. […]

August 29, 2022 - 3 minutesmins - By Liza Laws

News and Trends 24 Aug 2022

Potential new treatment for angioimmunoblastic T-cell lymphoma?

A type of blood cell cancer called angioimmunoblastic T-cell lymphoma (AITL) can develop as mutations accumulate with age in the stem cells from which the T cells in the blood develop. However, the underlying mechanism by which AITL develops was unknown. Now, a team from the University of Tsukuba in Japan have shown that B […]

August 24, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 18 Aug 2022

First patient on Innovative Cellular Therapeutics’ study looking at treating colorectal cancer

The first patient has been enrolled on a study to trial a treatment for relapsed or refractory metastatic colorectal cancer (R/R mCRC) in the U.S. Innovative Cellular Therapeutics (ICT), Inc. a clinical-stage biotechnology company developing a comprehensive portfolio of chimeric antigen receptor (CAR) T cell therapies made the announcement today (August 18). Tolerability The study […]

August 18, 2022 - 2 minutesmins - By Liza Laws

More News! 3 Aug 2022

Orca Bio announces Precision-T phase 3 study open and enrolling patients across US transplant centers

US-based Orca Bio, today announced Precision-T, its pivotal phase 3 study, is open, enrolling and treating 174 leukemia patients at more than 20 clinical trial sites. Precision-T is a randomized, open-label multi-center study that is evaluating the safety and efficacy of Orca Bio’s lead investigational high-precision cell therapy, Orca-T, compared to standard of care allogeneic […]

August 3, 2022 - 2 minutesmins - By Liza Laws

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us